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ABSTRACT
Hepatic stellate cells (HSC) play a major role in initiating the liver fibrogenic 
(wounding) response of the liver and can also orchestrate a pro-metastatic 
microenvironment in the liver in response to invading cancer cells. Here we explored 
the role of the hepatic stellate cells in colon carcinoma liver metastasis with emphasis 
on the contribution of the insulin-like growth factor (IGF) axis to their activation and 
function. To this end, we used mice with a Tamoxifen inducible liver IGF-I deficiency. 
We found that in mice with a sustained IGF-I deficiency, recruitment and activation 
of HSC into tumor-infiltrated areas of the liver were markedly diminished, resulting 
in decreased collagen deposition and reduced tumor expansion. In addition, IGF-I 
could rescue HSC from apoptosis induced by pro-inflammatory factors such as TNF-` 
known to be upregulated in the early stages of liver metastasis. Moreover, in surgical 
specimens, activated IGF-IR was observed on HSC-like stromal cells surrounding 
colorectal carcinoma liver metastases. Finally, IGF-targeting in vivo using an IGF-
Trap caused a significant reduction in HSC activation in response to metastatic colon 
cancer cells. Therefore, our data identify IGF as a survival factor for HSC and thereby, 
a promoter of the pro-metastatic microenvironment in the liver. IGF-targeting could 
therefore provide a strategy for curtailing the pro-metastatic host response of the 
liver during the early stages of liver metastasis.
INTRODUCTION
The liver is the most common site of metastases for 
carcinomas of the gastrointestinal tract. Liver metastases 
are frequently inoperable and are associated with poor 
prognosis, resulting in a 25–30% 5-year survival rate for 
cancers such as colorectal carcinoma [1]. The response of 
the liver to invading cancer cells is complex and involves 
various hepatic cells that can together orchestrate a pro-
metastatic microenvironment, promoting tumor expansion. 
A better understanding of the multifaceted response of the 
liver microenvironment is crucial to designing therapeutic 
strategies that can curtail or improve cure-rates for hepatic 
metastases. The hepatic stellate cells (HSC) are key 
players in the response of the liver to invading cancer cells 
[2]. In their quiescent state, HSC are located in the space of 
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Disse and identified by the content of vitamin A droplets, 
the expression of glial fibrillary acidic protein (GFAP) and 
to a lesser degree, desmin [3–4]. Upon activation, HSC 
differentiate into myofibroblast-like cells, increasing the 
expression of desmin and several other markers such as 
alpha-smooth muscle actin (α-SMA), tissue inhibitors 
of metalloproteinases (TIMPs) and type I collagen [3, 
5–6]. Activated HSC orchestrate the fibrogenic response 
of the liver to injury, altering the quality and quantity 
of the extracellular matrix (ECM) and producing the 
characteristic, type I collagen rich “scar” matrix [7]. The 
role of HSC in the liver fibrogenic response has been 
extensively studied, leading to identification of therapeutic 
targets for the treatment of liver inflammation and fibrosis 
[8–9]. Their role in liver metastasis, although documented 
[10], has however, received less attention and is not as 
well understood.
Tumor cells that metastasize to the liver and invade 
into the extra-sinusoidal space trigger an inflammatory 
response that is initiated mainly by Kupffer cells (KCs) 
and recruited neutrophils that, together, constitute the 
first line of defense and a major source of cytokine and 
chemokine production in the tumor microenvironment 
[11]. Among the factors produced by KC, tumor necrosis 
factor-α (TNF-α) can either induce apoptosis in sensitive 
cells or upregulate the expression of pro-metastatic factors 
such as IL-6 or TIMPs [12] and transforming growth 
factor-β (TGF-β) that can increase collagen synthesis [13], 
leading to fibrosis. Activated HSC release various growth 
factors such as epidermal growth factor (EGF), vascular 
endothelial growth factor (VEGF), and insulin-like growth 
factor-I (IGF-I) and metalloproteinases (MMP-2,-9,-13) 
[3] that together contribute to recruitment of endothelial 
cells and angiogenesis and promote tumor cell invasion 
and proliferation [10].
The IGF axis consists of two ligands; IGF-I and 
IGF-II, their receptors IGF-IR, the IGF-II/mannose 
6-phosphate receptor (IGF-II/M6-PR) and IGF-IR-insulin 
receptor hybrids, and six high affinity IGF binding proteins 
(IGFBPs). Endocrine IGF-I is produced by the liver under 
the control of growth hormone and mediates the latter’s 
growth-promoting functions. Under normal physiological 
conditions, the IGF-axis plays diverse roles in cellular 
metabolism, proliferation and differentiation [14]. It has 
also been implicated in all stages of malignant progression 
from tumor initiation to metastasis [15–16]. A recent study 
identified the IGF-I receptor (IGF-IR) as a risk factor for 
liver metastasis in colorectal carcinoma patients [17], but 
its precise function in this process remains to be fully 
understood. In vitro studies have shown that IGF-I can 
promote HSC activation [18] and in vivo, the IGF-II/
M6-PR was found to be up-regulated on activated HSC 
during liver fibrosis [19]. However, the role that IGF-I 
plays in HSC recruitment and activation in response to 
metastasizing tumor cells remains unknown.
In this study we explored the role of IGF-I in HSC 
activation during the early stages of colorectal carcinoma 
liver metastasis, using mice with a Tamoxifen (Tx) 
inducible liver IGF-I deficiency (iLID). We compared 
the effect of IGF-I depletion in 2 models; one of an 
acute IGF-I deficiency that was induced 2 days prior 
to tumor cell injection (iLID2D) and the other of a more 
sustained IGF-I deficiency induced 3 weeks prior to 
analysis (iLID3W). We found that a sustained (but not a 
short term) reduction in IGF-I levels markedly decreased 
the recruitment and activation of HSC in response to 
metastasizing colon cancer cells with consequences to 
metastatic expansion.
RESULTS
A sustained IGF-I deficiency alters the response 
of hepatic stellate cells to metastatic colon cancer 
cells
We previously reported that in mice with reduced 
plasma IGF-I levels from birth [20] or decreased IGF-I 
bioavailability [21], the incidence of experimental colon 
carcinoma liver metastases was markedly reduced and 
this coincided with an altered inflammatory response 
to the invading tumor cells and increased tumor cell 
apoptosis, respectively. The objective of the present study 
was to further investigate the effect of IGF-I depletion 
on the tumor microenvironment in the liver, in particular 
its role in regulating the recruitment and activation of 
hepatic stellate cells, events thought to orchestrate the pro-
metastatic host response in the liver. To this end, we used 
mice with a conditional liver Igf1 gene deletion induced by 
a single Tamoxifen (Tx) injection (iLID model). Depletion 
of liver IGF-I was induced 2 days (short term depletion - 
iLID2D) or 3 weeks (long term depletion - iLID3W) prior to 
tumor inoculation, as depicted in Figure 1A. A reduction 
in serum IGF-I levels could be observed within 24 hr of 
Tx injection and was sustained throughout the lives of 
the mice (Figure 1A). Littermate controls injected with 
sunflower oil (vehicle) or C57Bl/6 mice injected with 
Tx were used as controls. Mice were injected with 5x105 
colon carcinoma MC-38-GFP cells via the intrasplenic/
portal route and sacrificed 3 or 6 days later to quantify 
and determine the phenotype of HSC recruited into the 
tumor-infiltrated areas. In control mice, we observed an 
accumulation of activated HSC in areas invaded by the 
tumor cells as early as 3 days post tumor cell inoculation 
and this was also seen in iLID2D mice (Supplementary 
Figure S1). In iLID3W mice, however, the recruitment and 
activation of tumor-associated HSC were significantly 
reduced, as was also evident 6 days post tumor injection 
(Supplementary Figure S1, Figure 1B). To rule out any 
non-specific effects of Tx, HSC were also analyzed in 
tumor-injected C57Bl/6 mice that were pre-treated with 
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Tx, 2 days or 3 weeks earlier. In these mice, we observed 
no change in the recruitment or activation status of 
HSC relative to controls as measured 6 days post tumor 
injection (Figure 1C).
Reduced tumor colony size in mice with a 
sustained IGF-I deficiency
To determine the effect of reduced HSC recruitment 
on the growth of the hepatic metastases, mice were 
injected with 1x105 MC-38 cells via the intrasplenic/
portal route, livers removed 6 days later and formalin 
fixed, paraffin embedded (FFPE) sections prepared and 
H&E stained. We observed a significant reduction in 
colony size in iLID3W mice, as compared to oil-injected 
controls, but this was not observed in iLID2D mice (Figure 
2). These results suggested the following: 1. that the 
reduced levels of circulating IGF-I (of equal magnitude 
in iLID2D and iLID3W mice) was not itself sufficient to 
directly inhibit tumor cell growth in the liver, and 2. that 
the impaired recruitment and activation of HSC in the 
tumor microenvironment resulted in a reduction in the 
growth of metastases.
HSC-derived collagen production is decreased 
in mice with a sustained reduction in circulating 
IGF-I levels
HSC contribute to metastatic expansion by 
depositing ECM collagen and thereby promoting 
endothelial cell migration, angiogenesis and tumor cell 
invasion [22]. In livers of iLID3W mice injected with 
colon carcinoma MC-38 cells, we observed a reduction in 
collagen production as quantified by Sirius Red staining 
[23] (Figure 3A). To confirm that the observed reductions 
in HSC activation and ECM deposition in iLID3W mice 
were a direct consequence of IGF-I depletion and not 
the result of reduced tumor growth, we also analyzed 
HSC activation in a tumor - free model namely, the 
CCl4-induced liver fibrosis model known to be driven 
by activated HSC [24]. When collagen deposition in this 
model was quantified by Sirius Red staining, a similar 
reduction in HSC-mediated collagen deposition was 
observed in iLID3W mice, but this was not seen in iLID2D 
mice, as compared to their respective controls. This 
was also confirmed by qPCR for α-SMA and collagen 
1α1 (Supplementary Figure S2A and S2B). Moreover, 
Figure 1: Loss of hepatic stellate cell activation in mice with a sustained liver IGF-I deficiency. Shown in (A-left) is a 
schematic representation of the experimental design. MC-38-GFP (5x105) and Tamoxifen (Tx) (0.3 mg/mouse) injections are indicated by 
arrows and the day the mice were sacrificed by an X. Tx and vehicle (Oil) injected-iLID mice were bled every 2-3 days and IGF-I serum 
levels measure by ELISA. Results (A-right) are expressed as the means (±SEM) of 5-10 serum samples per time point (p<0.05 at all the 
time points analyzed). Shown in B. and C. are the results of experiments in which iLID (B) or C57Bl/6 (C) mice were injected with Tx or 
Oil, 2 days (iLID2D, C572D) or 3 weeks (iLID3W, C573W) prior to tumor injection and the animals sacrificed on day 3 (B-top) or 6 (B-bottom 
and C) to quantify recruitment and activation of HSC by IHC. For each experiment (B, C), a set of 15 - 20 sections from 3-5 mice per 
group were analyzed and the number of desmin+ or desmin+α-SMA+(aHSC) cells per tumor cell (x20 objective) were calculated. *p<0.05.
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Figure 2: Decreased growth of liver metastases in mice with a sustained IGF-I deficiency. iLID mice (n=3-5) were injected 
with Tx or Oil 2 days (iLID2D) or 3 weeks (iLID3W) prior to the intrasplenic/portal injection of 5x105 MC-38 cells, sacrificed 6 days later and 
FFPE liver sections prepared and H&E stained to quantify tumor colonies. Images on the right are representative of a set of 15 - 20 sections 
per group. Total surface area occupied by tumor cells (bar graph, left) was quantified by Image J (x10 objective, scale bar = 200μm). T: 
Tumor, L: Liver; *p<0.05.
Figure 3: A sustained IGF-I deficiency reduces collagen production in tumor-injected mice and treatment with an 
IGF-I inhibitor impairs HSC activation. iLID mice were injected with Tx or Oil 3 weeks (iLID3W) prior to intrasplenic/portal 
injection of 5x105 MC-38 cells. FFPE sections of the livers obtained 6 days post tumor injection were stained with Sirius Red and the 
red-stained areas quantified in a total of 20-50 fields derived from 3 - 4 animals per condition (x10 objective). Shown in (A-right) are 
representative images of Sirius Red –stained sections and in (A-left) results of the quantification performed by Image J expressed as the % 
of total surface area/field that was stained red (collagen). In a separate experiment (B). C57Bl/6 mice injected with 5x105 MC-38-GFP were 
treated i.v. with 10 mg/kg IGF-Trap or saline (Vh) as control, on days 2 and 4 post tumor injection and mice sacrificed on day 6. Activated 
HSC (desmin+α-SMA+) recruited into tumor-infiltrated areas were quantified and the results are expressed as % of all desmin+ cells/field in 
a set of 15-20 sections obtained from 3-5 animals per group (x40 objective) (B-left). Representative IHC images of tumor-infiltrated areas 
are shown on the right. Arrows denote activated hepatic stellate cells (aHSC); L- Liver, T- Tumor; *p<0.05
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treatment of wild-type mice with an IGF-IR targeting 
inhibitor, the IGF-Trap, that reduces IGF-I bioavailability 
and IGF-IR signaling in vivo [21], also significantly 
reduced HSC activation in response to tumor cells (Figure 
3B).
GH can compensate for reduced IGF-I 
production in mice with a short term IGF-I 
deficiency
Our results suggested that there was a fundamental 
difference between the hepatic microenvironments in mice 
with a short versus sustained IGF-I depletion. To gain 
insight into the underlying cause(s), we first measured 
serum levels of insulin and GH, because their production is 
regulated by serum IGF-I levels [25]. In the iLID mice, we 
found a significant increase in circulating GH levels from 
day 2 and up to one week post Tx injection, at which time 
the levels normalized to those observed in controls (Figure 
4A). This was not due to a recovery in circulating IGF-I 
levels which remained low for the entire experimental 
period, as shown in Figure 1A. During the first week 
post Tx injection, the increase in circulating GH levels 
was also reflected in a significant increase in the levels 
of phosphorylated STAT5 (pSTAT5), a transcription factor 
activated downstream of GH signaling, as seen in both 
total liver extracts and in HSC isolated from iLID mice, 
2 days post Tx injection (Figure 4B). STAT5 regulates 
IGF-I expression levels [26]. Indeed, we observed that in 
HSC obtained from iLID2D mice, IGF-I production levels 
were significantly higher than in HSC from iLID3W mice 
(Figure 4C), suggesting that autocrine IGF- signaling may 
be triggered in the former cells. To rule out a direct effect 
of GH on the tumor cells in iLID2D mice that could result 
in the production of pro-fibrogenic factors that activate 
HSC in a paracrine manner, MC-38 cells were treated 
with rhGH in vitro and qPCR used to analyze changes 
in growth factor expression. We found that expression 
levels of the pro-fibrogenic factors TGF-β, CTGF and 
PDGF were unaffected by GH stimulation (Supplementary 
Figure S3), suggesting that tumor-derived factors were 
not contributing to HSC activation in the presence of high 
circulating GH levels. As expected, IGF-I expression in 
the tumor cells did increase in response to GH, potentially 
contributing to the stimulation of HSC in iLID2D mice.
Taken together, these results suggested that the 
difference in the HSC response in these mice was due, 
at least in part, to a potential compensatory effect of GH 
in mice with a short term, but not a sustained, liver IGF-I 
depletion. Of interest, we observed an increase in serum 
insulin levels in iLID mice when analyzed at 2 days or 
3 weeks post Tx injection (Figure 4D), suggesting that 
Figure 4: Increased GH production and signaling in mice with short term IGF-I depletion. iLID mice were injected with 
Tx or Oil and blood was collected twice weekly for 3 weeks. GH (A) was measured by ELISA and the results are expressed as the means 
(±SEM) of 5-10 serum samples per time point. Proteins were extracted from livers or from isolated HSC obtained from 4 - 6 iLID2D or 
iLID3W mice (and respective controls) and analyzed by Western blotting (B) using the indicated antibodies (Supplementary Table S1). 
Representative blots for pSTAT-5, STAT5 and β-Actin that was used as a loading control are shown on top of the bar graphs. Results are 
expressed as mean (±SEM) fold increase relative to the respective control (n=6). IGF-I levels in cell lysates of isolated HSC (C) were 
measured using an ELISA. The results are expressed as mean (±SEM) concentration detected in the indicated cells (n=3). Blood insulin 
levels (D) were measured in the indicated mice after a 6 hr fasting using an ELISA. The results, expressed as ng/ml are means (±SEM) of 
5-10 serum samples per time point. NS, not significant *p<0.05
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the divergent HSC activation levels and differences 
in collagen production and tumor growth observed in 
these mice were not likely due to differences in insulin 
production levels and metabolism.
A sustained reduction in circulating IGF-I levels 
affects IGF-IR expression and activation levels 
in HSC
The above results implicated IGF-I in HSC 
activation in response to invading tumor cells. In HSC 
surrounding metastatic tumor cells in the liver, we found 
high levels of activated IGF-IR and this was markedly 
reduced in iLID3W, but not iLID2D mice (Figure 5A). 
Moreover, when HSC were isolated from iLID mice and 
IGF-IR expression and activation levels analyzed by flow 
cytometry and Western blotting, we found a significant 
reduction in IGF-IR expression and activation in HSC 
isolated from iLID3W, but not iLID2D mice as compared 
to the respective controls (Figure 5B). The data suggest 
that in mice with a short term IGF-I deficiency, HSC may 
compensate for lower circulating IGF-I levels by increased 
GH-induced autocrine IGF signaling. This compensatory 
mechanism is not, however, available to HSC exposed to 
a sustained reduction in hepatic IGF-I levels as GH levels 
decline overtime (See proposed model in Figure 8).
IGF-I is a survival factor for HSC subjected 
to the pro-apoptotic effects of inflammatory 
cytokines
To test the effect of IGF-I on HSC more directly, 
we isolated quiescent, vitamin A+ HSC from the livers 
of wild type mice. We confirmed that treatment of the 
cultured cells with 100 ng/ml IGF-I for 5 min activated 
both the PI3K/AKT and MEK/ERK signaling pathways 
(Figure 6A) known to be engaged downstream of the 
IGF-IR [27]. HSC cultured in the presence of IGF-I or 
IGF-II had significantly increased α-SMA expression 
levels, as assessed by immunohistochemistry (Figure 
6B), suggesting that these ligands could directly activate 
the cells. Quiescent HSC are located in proximity to 
hepatocytes – the major source of endocrine IGF-I. This 
suggests that under conditions of homeostasis, they are 
insensitive to IGF-I induced activation but that they may 
become sensitized under pathological conditions such as 
inflammation and fibrogenesis. Both acute and chronic 
liver diseases are characterized by elevated serum levels 
of TNF-α and TGF-β. We asked whether IGF-I can 
attenuate potential pro-apoptotic effects of these factors 
and in this way, provide a survival advantage to HSC 
under these pathological conditions. We found that freshly 
isolated murine HSC underwent apoptosis in the presence 
of TNF-α and TGF-β, when administered alone or in 
combination. These cells were, however, rescued from cell 
death in the presence of IGF-I (Figure 6C), suggesting that 
under conditions of liver injury, IGF-IR may be engaged 
and act as a survival factor for HSC (see Figure 8).
IGF-IR is phosphorylated in activated stromal 
cells surrounding hepatic metastases in 
colorectal carcinoma patients
Finally, to determine the broader relevance of our 
findings, we analyzed by IHC surgical resections from 
chemo-naive colorectal carcinoma patients that underwent 
partial hepatectomy to remove liver metastases. Cryostat 
sections were immunostained with antibodies to α-SMA 
and pIGF-IR to identify activated HSC in which IGF-
IR signaling was induced. In the stromal interface at the 
edge of the metastases, multiple spindle-shaped cells co-
expressing α-SMA and pIGFIR could be identified (Figure 
7), implicating the IGF-IR in the stromal response of the 
liver to CRC metastases in the clinical disease.
DISCUSSION
Our results show that in a liver microenvironment 
altered by a sustained IGF-I deficiency, HSC recruitment 
and activation during the early stages of colon cancer 
metastasis are diminished, resulting in reduced growth of 
metastatic tumor cells. Taken together, they implicate the 
IGF-IR/IGF axis in the regulation of HSC survival and 
activation and thereby, in orchestrating the pro-metastatic 
response of the microenvironment to invading cancer cells. 
HSC activation and the growth of metastases are inter-
dependent. Our finding of reduced HSC activation and 
type I collagen production in a tumor-free model of liver 
injury induced in iLID3W mice by CCl4 suggests that the 
reduction in HSC activation in mice with a sustained IGF-I 
depletion was the consequence rather than the cause of 
reduced metastasis, indicating that the IGF axis is involved 
in the wounding response of the liver, independently of the 
trigger. In the context of metastasis, a reduction in type 
I collagen production could result in reduced endothelial 
cell migration, loss of angiogenesis and reduced tumor 
invasion [22], all leading to reduced tumor expansion, as 
seen in our model. Our results suggest that the reduction 
in HSC activation was associated with reduced IGF-IR 
expression levels on HSC, implying that physiological 
IGF-I levels are required to maintain IGF-IR expression 
levels on these cells. Interestingly, a similar reduction in 
IGF-IR expression levels in neutrophils was reported in 
mice with a sustained (but not short term) blockade of 
IGF-IR signaling, mediated by the administration of an 
anti IGF-IR antibody (AMG-479) for 3 weeks [28].
In mice with a short term IGF-I deficiency, no 
reductions in HSC recruitment or the growth of metastases 
were observed. Our results suggest that in these mice, GH 
levels were transiently increased, likely as a feedback 
response to reduced IGF-I bioavailability [25]. Moreover, 
IGF-I production in the HSC was increased and this could 
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Figure 6: Increased IGF-IR signaling, activation and survival in HSC stimulated by IGF-I in vitro. HSC were isolated 
from normal C57Bl/6 female mice (n=6) and cultured in collagen coated (5μg/cm2) 6 - (A), 8- (B), or 24- (C), well plates. Western 
blotting with the indicated antibodies (A) was performed on total cell lysates following stimulation of the HSC for 5 minutes with 100 
ng/ml rmIGF-I and the bands analyzed by laser densitometry and quantified using the Image J software. Shown on the left are the results 
of a representative immunoblot out of 3 performed and in the bar graphs the means (±SEM) of 3 separate experiments. To analyze HSC 
activation (B) or apoptosis (C), the cells were cultured first for 24 h in medium containing 10% FBS DMEM (cDMEM), and then treated (or 
not) for 3 days (B) or 24 hr (C) with rmIGF-I, rmIGF-II, TNF-α and TGF-β at the indicated concentrations in serum free medium (SF). Cells 
(B) were fixed with a methanol: acetone (1:1) solution and stained with DAPI (blue), and antibodies to α-SMA (red) and desmin (green). 
Representative images are shown on the bottom. Apoptosis (C) was measured using the Cell Death ELISA kit. Results in the bar graph are 
based on measurements of absorbance (at 405 nm) in triplicate samples derived from two independent experiments and are expressed as 
means (±SEM) of fold change relative to serum starved cells that were assigned a value of 1. *p<0.05
Figure 5: Decreased IGF-IR levels and reduced IGF-IR activation in hepatic stellate cells obtained from mice with a 
sustained IGF-I deficiency. In FFPE sections derived from tumor cell injected mice, phospho-IGF-IR (pIGFIR) levels were analyzed by 
IHC (A) and the proportion of pIGF-IR+desmin+ cells in the total desmin+ population/field were calculated. Results in the bar graph (right) are 
based on a set of 15 - 20 sections derived from 3-5 mice per group (x40 objective) and are expressed as means (±SEM). Representative IHC 
images are shown on the left. Arrows denote pIGFIR+ HSC. HSC were isolated from iLID2D or iLID3W mice (and respective controls) and 
analyzed by flow cytometry (B-left) or Western blotting (B-right) using antibodies to the α subunit of IGF-IR and pIGF-IR, respectively and 
β-actin as a loading control. Results of flow cytometry are means (±SEM) of 3 analyses and are expressed as a ratio to the respective vehicle-
injected controls that were assigned a value of 1. Results of the WB analysis are based on 6 samples and are expressed as mean fold change 
(±SEM) relative to the respective controls that were assigned a value of 1. Results of a representative immunoblot are shown on the top. *p<0.05.
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Figure 8: A model, postulated based on our data, for the role of IGF-I in HSC survival and activation and the effects of 
IGF-I depletion on CRC liver metastasis. In the presence of physiological serum IGF-I levels (A) HSC can be rescued from inflammation- 
induced apoptosis and are activated in response to tumor cell invasion, altering the microenvironment by ECM deposition that promotes 
angiogenesis and tumor expansion. Under conditions of short-term serum IGF-I depletion (B) serum GH levels are transiently increased and 
may compensate for the lack of IGF-I by triggering autocrine IGF-I/IGF-IR signaling in HSC via STAT5 signaling, thereby rescuing them from 
apoptosis. Under conditions of sustained IGF-I depletion (C) as serum GH levels normalize, the HSC become more susceptible to TGF-β and 
TNF-α- induced apoptosis and can no longer contribute to the pro-metastatic microenvironment required for tumor growth.
Figure 7: Myofibroblasts at the periphery of colorectal carcinoma liver metastases express activated IGF-IR. Adjacent frozen 
tissue sections were processed for single immunoperoxidase staining using a polyclonal Ab to pIGFIR (A, B) or an anti- α-SMA Mab C, D. 
The antibodies were visualised with NovaRed. Black squares in (A) and (C) represent the area shown in higher magnification in (B, D). Shown 
(C, D ) are representative images from one of 6 livers analyzed. In all the specimens examined, the majority (over 80%) of the immunoreactivity 
for pIGFIR was seen in spindle-shaped cells (arrows in A, B) at the rim of the metastases (indicated with Ca) in the tumor-stromal interface 
(indicated by St). These spindle-shaped cells were identified by staining adjacent sections for α-SMA (a marker of myofibroblasts). All pIGFIR-
positive spindle-shaped cells were α-SMA+, identifying them as myofibroblasts (arrow in C, D). pIGFIR immunoreactivity was also observed 
in polymorphonuclear cells (presumably neutrophils) close to the metastatic lesions (data not shown). Bars: ~40 μm (A, C) and ~20 μm (B, D).
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have resulted in autocrine IGF-IR activation that could, 
in turn, compensate for loss of liver IGF-I production and 
maintain IGF-IR expression levels (A postulated model 
is depicted in Figure 8). This mechanism appears to be 
lacking in HSC exposed to a sustained reduction in IGF-I 
levels, partially because GH levels return to their basal 
levels within a week post Tamoxifen treatment and also 
because of their reduced IGF-IR expression levels. The 
differences in the outcome of IGF-I deficiency in these two 
models also indicate that the effect of reduced circulating 
IGF-I on metastatic expansion was, at least in part, indirect 
acting via changes to the tumor microenvironment.
IGF-I is a mitogenic and survival factor for various 
cell types and these effects are mediated via the MEK/
ERK and PI3K/AKT pathways, respectively [27]. Indeed, 
we show here that these pathways were activated in 
isolated HSC following a brief exposure to IGF-I. The 
increased activation of HSC cultured in the presence 
of IGF-I (or IGF-II) as reflected in upregulated α-SMA 
expression is consistent with findings by others that 
implicated the ERK and AKT pathways in increased type 
I collagen synthesis in IGF-I-stimulated human HSC [29]. 
Experimental models of fibrosis have provided conflicting 
results on the role of IGF-I in this process. For example, 
IGF-I therapy was shown to improve liver fibrosis in a bile 
duct ligation (BDL) model, where the underlying cause 
is cholestasis [30]. Recent studies have, however, shown 
that portal fibroblasts and not HSC are the major players in 
this model of liver injury [24], suggesting that this process 
may be driven by other factors.
In normal livers, HSC can be exposed to hepatocyte-
derived IGF-I, yet remain quiescent. This suggests that 
the role of IGF-I is complex and that other factors may 
be involved in generating conditions permissive for IGF-
induced HSC activation. The entry of metastatic tumor 
cells into the liver has been shown to trigger a rapid 
release of pro-inflammatory cytokines including TNF-α 
[31]. Tumor cell invasion also appears to recapitulate 
some aspects of the liver wounding response triggering 
HSC activation, ECM deposition and the release of growth 
factors such as TGF-β, EGF, VEGF and IGF-I. Our data 
suggest that HSC may be susceptible to apoptosis in this 
microenvironment rich in TNF-α and TGF-β and that 
IGF-I may act as a survival factor rescuing these cells 
from death and promoting their recruitment and activation.
In surgical specimens of colorectal carcinoma liver 
metastases, we observed stromal cells co-expressing 
α-SMA and pIGFIR in the periphery of the metastatic 
tumors, consistent with our findings in the mouse model. 
Other types of stromal cells such as bone marrow derived 
fibrocytes and portal fibroblasts have been shown to play 
a role in the fibrogenic response of the liver [32] and may 
also be involved in the hepatic response to liver metastases 
[33]. While our data cannot definitively identify these cells 
as HSC in origin, they do strongly implicate IGF-IR in the 
response of the liver microenvironment to metastatic CRC.
To our knowledge, our study is the first to show 
that IGF-I plays a direct and essential role in HSC 
survival and activation in the context of liver metastasis, 
thereby identifying this axis as a target in the tumor 
microenvironment. Taken together with our previous 
findings that an IGF-Trap could markedly reduce colon 
cancer liver metastasis [21], the present data suggest 
that this effect was mediated, at least in part, through 
modulation of the pro-metastatic liver response to 
disseminating cancer cells.
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors' 
institutional review board.
Animals
All mouse experiments were carried out in strict 
accordance with the recommendations of the Canadian 
Council on Animal Care (CCAC) ‘‘Guide to the Care and 
Use of Experimental Animals’’ and under the conditions 
and procedures approved by the Animal Care Committee 
of McGill University (AUP # 5260). C57Bl/6 female 
mice were obtained from Charles River Laboratories 
(St. Constant, QC, Canada) and used for the experiments 
at the age of 7-10 wks. Mice with an inducible, liver 
specific IGF-I deficiency (iLID) were generated and their 
phenotype confirmed as described in detail previously 
[20]. Briefly, in these mice, a single Tamoxifen (Tx) 
injection results in gene recombination by activating the 
Cre recombinase gene under the control of a liver specific 
anti-trypsin 1 α promoter. The inducible igf1 deletion 
results in a ~60% reduction in serum IGF-I levels within 
~18 hr of a single i.p. injection of 0.3 mg Tx per mouse 
[34]. iLID breeder mice were originally obtained as a gift 
from Dr. Shoshana Yakar (New York University, NY) and 
a colony was maintained at the McGill University Health 
Center Animal facility, as per the guidelines of the McGill 
University Animal Care Committee. Female iLID and 
C57Bl/6 mice were injected either with Tx or with the 
vehicle, sunflower oil, as control [20, 34].
Cells
The murine colon carcinoma MC-38 cells were 
originally from an NCI repository and were obtained as a 
kind gift from Dr. Shoshana Yakar (New York University, 
NY) in 2005. They were recently authenticated by Didion 
and colleagues using SNP profiling as described [35]. The 
cells were transfected with a pEGL plasmid expressing 
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the Green Fluorescent Protein (GFP) and maintained 
in DMEM supplemented with 10% FBS, as described 
elsewhere [36]. The cells were periodically tested for 
mouse and human pathogens and mycoplasma infection, 
as per the McGill University Animal Care committee and 
the McGill University Biohazard committee guidelines, 
and were last confirmed to be pathogen and mycoplasma 
free in 2015. To avoid cross-contamination and phenotype 
changes, these cells were maintained as a frozen stock 
and cultured for only 2 - 4 weeks prior to use in the 
experiments. Authentication of these cell lines based on 
morphology and metastatic phenotype was performed 
regularly, and no phenotype changes were observed 
throughout the duration of this study.
Antibodies and reagents
All antibodies used in this study are listed in 
Supplementary Table S1. Carbon tetrachloride (CCl4) and 
sunflower oil were purchased from Sigma (St. Louis, MO).
Experimental metastasis assays
Experimental hepatic metastases were generated 
by the intrasplenic/portal injections of 5x105 MC-38-GFP 
cells in 100 μl of DMEM followed by splenectomy 1 min 
later, as we described in detail previously [37–38].
IHC and confocal microscopy
Following the specified treatment, the livers were 
perfused, first with PBS and then with 4 ml of a 4% 
paraformaldehyde solution. The perfused livers were 
placed in 4% paraformaldehyde for 48 hr and then in 
30% sucrose for an additional 48 hr, before they were 
stored at -80°C. For IHC, 10 μm cryostat sections were 
prepared, treated with a blocking solution (1% bovine 
serum albumin (BSA), 1% fetal bovine serum (FBS) 
in PBS) and then incubated overnight at 4°C with the 
primary antibodies used at the indicated dilutions (see 
Supplementary Table S1) and followed by the appropriate 
Alexa Fluor conjugated secondary antibodies for 1 hr at 
RT. Sections stained with the secondary antibodies only 
were used as controls in all the experiments. Tumor 
infiltrated areas were identified based on GFP expression 
and HSC identified based on the expression of the cell 
surface markers desmin and α-SMA. For immunodetection 
of desmin, two different antibodies were used (see 
Supplementary Table S1) to ensure antigen specificity. 
The sections were mounted in the Prolong Gold anti-
fade reagent (Molecular Probes, Eugene, Oregon, USA) 
and confocal images were captured with a Zeiss LSM 
780 microscope with a spectrum detection capability. 
Immunostained cells were quantified blindly using the 
Image J software in 30-50 images acquired per section.
Liver fibrosis model
Liver fibrosis was induced by intra-gastric gavage 
with 200 μl of 25% carbon tetrachloride (CCl4) in 
sunflower oil, twice weekly for 6 weeks [23]. Formalin-
fixed livers were stained with Sirius Red and the fibrotic 
surface area quantified using the Image J software. Liver 
fragments were snap frozen and stored at -80°C for RNA 
extraction and qPCR analysis as described below.
Quantitative real time RT-PCR
RNA was extracted from liver tissue or MC-
38 cells using the Trizol reagent (Life Technologies, 
Inc., Burlington, Ontario, Canada) according to the 
manufacturer’s instructions. One μg of total RNA was 
reverse transcribed as described previously [31] and 
quantitative real-time RT-PCR was performed in a 
BioRad LightCycler (BioRad, Hercules, CA , USA) using 
SYBR (Roche, ON, Canada) and the primers listed in 
Supplementary Table S2. The Iq5 software was used for 
data analysis.
IGF-Trap treatment
C57Bl/6 female mice were injected i.v. with 
10 mg/kg of the IGF-Trap [21] (or vehicle for control), 2 
and 4 days following the intrasplenic/portal inoculation of 
5x105 MC-38 cells. Livers were processed for IHC, 6 days 
post tumor injection.
Measurement of blood GH, IGF-I and insulin
Blood was collected from mice 6 hr after fasting. 
Serum insulin and GH levels were measured using the 
Mercodia mouse insulin ELISA Kit (Mercodia AB, 
Uppsala, Sweden) and the rat/mouse GH ELISA Kit 
(EMD Millipore, ON, Canada), respectively. IGF-I levels 
in the serum or in protein extracts were analyzed using the 
Mouse/Rat IGF-I Quantikine ELISA Kit (R&D Systems, 
Minneapolis, MN, USA).
Isolation of HSC
HSC were isolated by Percoll density gradient 
centrifugation following liver perfusion and consecutive 
digestion with 0.2% pronase and 0.05% collagenase/
pronase solutions, as described previously [23, 39]. 
Isolated HSC were cultured in collagen coated plates 
(5μg/cm2, Roche, Basel, Switzerland) with 10% FBS 
enriched DMEM for the indicated duration or used for 
protein extraction, as described below. Isolated HSC 
were stimulated with 50 or 100 ng/ml recombinant mouse 
IGF-I (R&D Systems, Minneapolis, MN, USA) or with 
250 or 500 ng/ml rhIGF-II (BioVision, San Francisco, 
CA, USA) and the medium replenished daily for 3 days, 
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before the cells were fixed in a chilled acetone:methanol 
solution (1:1) and immunostained with anti- desmin 
and/or α-SMA antibodies. Apoptosis induced by serum 
starvation, TNF-α (10 ng/ml) or TGF-β (100 pM) was 
measured using the Cell Death detection ELISA (Roche, 
ON, Canada), as instructed by the manufacturer. Prior 
to analyzing activation of IGF-I signaling, HSC were 
stimulated for 5 minutes with 100 ng/ml rmIGF-I (R&D 
Systems, Minneapolis, MN, USA).
Western blot analysis
Livers or cells were lysed with RIPA buffer (25 mM 
Tris-HCl pH 7.6, 150 mM NaCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS) containing a protease 
inhibitor cocktail (Roche, Basel, Switzerland). The lysate 
proteins were separated by SDS-PAGE and Western 
blotting performed as previously described [40]. Primary 
and secondary antibodies were used at the dilutions 
detailed in Supplementary Table S1. Densitometry was 
performed using the Image Quant LAS 4000 image 
analysis system (GE Healthcare, ON, Canada) and the 
images analyzed using the Image J software.
Flow cytometry
IGF-IR expression levels in isolated, vitamin A – 
containing HSC were analyzed by flow cytometry using the 
FACSCanto II RUO system (BD Biosciences, ON, Canada). 
Gating was based on vitamin A positivity, as detected by 
violet laser (405 nm), and IGF-IR positivity [24].
Patient material
All samples were obtained from patients undergoing 
partial hepatectomy for colorectal cancer liver metastases 
at the Northern General Hospital, Sheffield, UK, following 
signed informed consent. Specimens were obtained in the 
operating theatre, sampled at the tumor/liver interface, 
frozen in isopentane/dry-ice within 30 min post resection, 
embedded in O.C.T. (Sakura Finetek, Tokyo, Japan) 
and stored in liquid nitrogen until analyzed. The group 
comprised of 4 males and 2 females, all of whom developed 
metachronous metastases. The protocol was approved by 
the Bradford Research Ethics Committee (08/H1302/73, 
Sheffield Teaching Hospitals Research Office ref: 14958).
Immunohistochemistry
For analysis of patients’ specimens five μm thick 
cryostat sections were fixed in neutral buffered 4% 
formalin at RT for either 5 (p-IGFIR) or 30 (α-SMA) min. 
Endogenous peroxidase activity was blocked by three 15 
min incubations in 1% H2O2. The sections were washed 
in Tris-buffered saline (TBS, 50mM Tris-HCL, 150 mM 
NaCl) containing 0.5% Triton X-100 (TBS-T) and placed in 
Shandon racks with immunostaining cover plates (Thermo 
Shandon, Pittsburgh, PA) for further incubation. Antibodies 
were diluted in Antibody Diluent with Background-
Reducing Components (S3022, Dako) to concentrations 
of 10 (p-IGFIR, Abcam) and 0.35 (α-SMA, Dako) μg/ml 
and incubated overnight at 4°C. Primary antibodies were 
detected with EnVision™ Horseradish Peroxidase rabbit 
or mouse reagents. Each incubation step was followed 
by washes in TBS-T. The sections were developed with 
NovaRed (Vector laboratories, Burlingame, CA) and 
counterstained in Mayer’s haematoxylin. Finally, slides 
were dehydrated and mounted using a Dako Coverslipper.
Statistical analysis
The one- or two-way ANOVA was used to analyze 
differences in HSC recruitment or activation and for all 
the in vitro data. The student t-test was used to analyze 
all other in vivo data, as well as Western blot and ELISA 
results. Statistical significance was defined as a p-value of 
less than 0.05.
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